VJHemOnc is committed to improving our service to you

ASH 2017 | ASH 2017: combination therapy for CLL highlights

VJHemOnc is committed to improving our service to you

Barbara Eichhorst

Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the take-home messages from data for combination therapy for CLL presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter